来那度胺影响多发性骨髓瘤细胞系RPMI8226中cereblon蛋白的表达水平。
Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
作者信息
Yang D Y, Ren J H, Guo X N, Guo X L, Cai X Y, Guo X F, Zhang J N
机构信息
Department of Hematology, Secondary Hospital of HeBei Medical University, HeBei Hematology Institute, Shijiazhuang, HeBei Province, China.
Department of Hematology, Secondary Hospital of HeBei Medical University, HeBei Hematology Institute, Shijiazhuang, HeBei Province, China
出版信息
Genet Mol Res. 2015 Oct 29;14(4):13588-94. doi: 10.4238/2015.October.28.19.
We investigated the mechanisms of action of immuno-modulatory drug (lenalidomide) on the protein expression of cereblon (CRBN) and their therapeutic targets in the multiple myeloma cell line RPMI8226. The multiple myeloma cell line RPMI8226 was cultured and treated with different concentrations of lenalidomide and bortezomib to determine the proliferation inhibition rate, apoptosis rate, and protein expression of CRBN. The results revealed that both lenalidomide and bortezomib inhibited the proliferation of RPMI8226 and promoted cell apoptosis. However, the protein expression of CRBN decreased signifi-cantly after treatment with lenalidomide, while bortezomib had no effect on the expression of CRBN. We confirmed that CRBN may be a target of lenalidomide.
我们研究了免疫调节药物（来那度胺）对多发性骨髓瘤细胞系RPMI8226中cereblon（CRBN）蛋白表达的作用机制及其治疗靶点。培养多发性骨髓瘤细胞系RPMI8226，并用不同浓度的来那度胺和硼替佐米进行处理，以确定增殖抑制率、凋亡率和CRBN的蛋白表达。结果显示，来那度胺和硼替佐米均抑制RPMI8226的增殖并促进细胞凋亡。然而，来那度胺处理后CRBN的蛋白表达显著下降，而硼替佐米对CRBN的表达没有影响。我们证实CRBN可能是来那度胺的一个靶点。
Zotero 插件